medicine: vancomycin

vancomycin description

Go to trade names and prices








Vancomycin (INN) (pronounced /ˌvæŋkɵˈmaɪsɪn/) is a glycopeptide antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been reserved as a drug of "last resort", used only after treatment with other antibiotics had failed, although the emergence of vancomycin-resistant organisms means that it is increasingly being displaced from this role by linezolid and daptomycin.

History

Vancomycin was first isolated by EC Kornfeld (working at Eli Lilly) from a soil sample collected from the interior jungles of Borneo by a missionary. The organism that produced it was eventually named Amycolatopsis orientalis. The original indication for vancomycin was for the treatment of penicillin-resistant Staphylococcus aureus.

The compound was initially labelled compound 05865, but was eventually given the generic name, vancomycin (derived from the word "vanquished"). One advantage that was quickly apparent was that staphylococci did not develop significant resistance despite serial passage in culture media containing vancomycin. The rapid development of penicillin-resistance by staphylococci led to the compound being fast-tracked for approval by the FDA in 1958. Eli Lilly first marketed vancomycin hydrochloride under the trade name Vancocin.

Vancomycin never became first line treatment for Staphylococcus aureus for several reasons:

The drug must be given intravenously, because it is not absorbed orally.
β-lactamase-resistant semi-synthetic penicillins such as methicillin (and its successors, nafcillin and cloxacillin) were subsequently developed.
Early trials used early impure forms of vancomycin ("Mississippi mud") which were found to be toxic to the ears and to the kidneys; these findings led to vancomycin being relegated to the position of a drug of last resort.

In 2004, Eli Lilly licensed vancocin to ViroPharma in the U.S., Flynn Pharma in the UK and Aspen Pharmacare in Australia. The patent expired in the early 1980s, but the FDA has not authorized the sale of any generic versions in the USA.

Biosynthesis

Figure 1: Modules and Domains of Vancomycin assembly.

Vancomycin biosynthesis occurs via different nonribosomal protein synthases (NRPSs). The enzymes determine the amino acid sequence during its assembly through its 7 modules. Before Vancomycin is assembled through NRPS, the amino acids are first modified. L-tyrosine is modified to become the β-hydroxychlorotyrosine (β-hTyr) and 4-hydroxyphenylglycine (HPG) residues. On the other hand, acetate is used to derive the 3,5 dihydroxyphenylglycine ring (3,5-DPG).

Figure 2: Linear heptapeptide which consists of modified aromatic rings

Nonribosomal peptide synthesis occurs through distinct modules that can load and extend the protein by one amino acid through the amide bond formation at the contact sites of the activating domains. Each module typically consists of an adenylation (A) domain, a peptidyl carrier protein (PCP) domain, and a condensation (C) or elongation domain. In the A domain, the specific amino acid is activated by converting into an aminoacyl adenylate enzyme complex attached to a 4’phosphopantetheine cofactor by thioesterification The complex is then transferred to the PCP domain with the expulsion of AMP. The PCP domain uses the attached 4’-phosphopantethein prosthetic group to load the growing peptide chain and their precursors. The organization of the modules necessary to biosynthesize Vancomycin is shown in Figure 1. In the biosynthesis of Vancomycin, additional modification domains are present, such as the epimerization (E) domain, which is used isomerizes the amino acid from one stereochemistry to another, and a thioesterase domain (TE) is used as a catalyst for cyclization and releases of the molecule via a thioesterase scission.

Figure 3: Modifications that are necessary for Vancomycin to become biologically active.

A set of multienzymes (peptide synthase CepA, CepB, and CepC) are responsible for assembling the heptapeptide. (Figure 2). The organization of CepA, CepB, and Cep C closely resembles other peptide synthases such as those for surfactin (SrfA1, SrfA2 and SrfA3) and gramicidin (GrsA and GrsB). Each peptide synthase activates codes for various amino acids in order to activate each domain. CepA codes for modules 1, 2 and 3, CepB codes for modules 4,5,and 6, and CepC codes for module 7 codes. The three peptide synthases are located at the start of the region of the bacterial genome linked with antibiotic biosynthesis and spans 27kb.

After the linear heptapeptide molecule is synthesized, Vancomycin has to further undergo post-translational modifications, such as oxidative cross-linking and glycosylation, in trans by distinct enzymes, referred to as tailoring enzymes, in order to become biologically active (Figure 3). To convert the linear heptapeptide, eight enzymes, Open Reading Frames (ORF) 7, 8, 9, 10, 11, 14, 18, 20, and 21 are used. The enzymes ORF 7, 8,9 and 20 are P450 enzymes, ORF 10 and 18 show to nonheme haloperoxidases and ORF 9 and 14 are identified as putative hydroxylation enzymes. With the help of these enzymes, β-hydroxyl groups are introduced onto tyrosine residues 2 and 6 and coupling occurs for rings 5 and 7, rings 4 and 6, and rings 4 and 2. In addition, a haloperoxidase is used to attach the chlorine atoms onto rings 2 and 6 via an oxidative process.

Pharmacology and chemistry

It is a branched tricyclic glycosylated nonribosomal peptide produced by the fermentation of the Actinobacteria species Amycolatopsis orientalis (formerly designated Nocardia orientalis).

Vancomycin acts by inhibiting proper cell wall synthesis in Gram-positive bacteria. The mechanism inhibited, and various factors related to entering the outer membrane of Gram-negative organisms mean that vancomycin is not active against Gram-negative bacteria (except some non-gonococcal species of Neisseria).

Specifically, vancomycin prevents incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits into the peptidoglycan matrix; which forms the major structural component of Gram-positive cell walls.

The large hydrophilic molecule is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Normally this is a five-point interaction. This binding of vancomycin to the D-Ala-D-Ala prevents the incorporation of the NAM/NAG-peptide subunits into the peptidoglycan matrix.

Vancomycin exhibits atropisomerism — it has two chemically distinct rotamers owing to the rotational restriction of the chlorotyrosine residue (on the right hand side of the figure). The form present in the drug is the thermodynamically more stable conformer and, importantly, has more potent activity.

Clinical use

Indications

Vancomycin is indicated for the treatment of serious, life-threatening infections by Gram-positive bacteria which are unresponsive to other less toxic antibiotics. In particular, vancomycin should not be used to treat methicillin-sensitive Staphylococcus aureus because it is inferior to penicillins such as nafcillin.

The increasing emergence of vancomycin-resistant enterococci has resulted in the development of guidelines for use by the Centers for Disease Control (CDC) Hospital Infection Control Practices Advisory Committee. These guidelines restrict use of vancomycin to the following indications:

treatment of serious infections caused by susceptible organisms resistant to penicillins (methicillin-resistant Staphylococcus aureus and multi-resistant Staphylococcus epidermidis (MRSE)) or in individuals with serious allergy to penicillins
pseudomembranous colitis (relapse or unresponsive to metronidazole treatment)
For treatment of infections caused by gram-positive microorganisms in patients who have serious allergies to beta-lactam antimicrobials. (http:wonder.cdc.gov/wonder/prevguid/m0039349/m0039349.asp)
antibacterial prophylaxis for endocarditis following certain procedures in penicillin-hypersensitive individuals at high risk [citation needed]
surgical prophylaxis for major procedures involving implantation of prostheses in institutions with a high rate of MRSA or MRSE [citation needed]

Adverse effects

Although vancomycin levels are usually monitored, in an effort to reduce adverse events, the value of this is not beyond debate. Peak and trough levels are usually monitored, and for research purposes, the area under the curve is also sometimes used. Toxicity is best monitored by looking at trough values.

Common adverse drug reactions (≥1% of patients) associated with IV vancomycin include: local pain, which may be severe and/or thrombophlebitis.

Damage to the kidneys and to the hearing were a side effect of the early impure versions of vancomycin, and these were prominent in the clinical trials conducted in the mid-1950s. Later trials using purer forms of vancomycin found that nephrotoxicity is an infrequent adverse effect (0.1–1% of patients), but that this is accentuated in the presence of aminoglycosides.

Rare adverse effects (<0.1% of patients) include: anaphylaxis, toxic epidermal necrolysis, erythema multiforme, red man syndrome (see below), superinfection, thrombocytopenia, neutropenia, leucopenia, tinnitus, dizziness and/or ototoxicity (see below).

Lately it has been emphasized that vancomycin can induce platelet-reactive antibodies in the patient, leading to severe thrombocytopenia and bleeding with florid petechial hemorrhages, ecchymoses, and wet purpura.

Dosing considerations

Intravenous vs oral administration

Vancomycin needs to be given intravenously (IV) for systemic therapy since it does not cross through the intestinal lining. It is a large hydrophilic molecule which partitions poorly across the gastrointestinal mucosa. The only indication for oral vancomycin therapy is in the treatment of pseudomembranous colitis, where it must be given orally to reach the site of infection in the colon. Following oral administration, the fecal concentration of vancomycin is around 500 µg/ml (sensitive strains of C. difficile have a mean inhibitory concentration of ≤2 µg/ml)

Inhaled vancomycin has also been used (off-label), via nebulizer, for treatment of various infections of the upper and lower respiratory tract. The caustic nature of Vancomycin makes IV therapy using midline PICC lines a risk for thrombophlebitis.

Red man syndrome

Vancomycin must be administered in a dilute solution slowly, over at least 60 minutes (maximum rate of 10 mg/minute for doses >500 mg). This is due to the high incidence of pain and thrombophlebitis and to avoid an infusion reaction known as the red man syndrome or red neck syndrome. This syndrome, usually appearing within 4–10 minutes after the commencement or soon after the completion of an infusion, is characterized by flushing and/or an erythematous rash that affects the face, neck and upper torso. These findings are due to non-specific mast cell degranulation and are not an IgE mediated allergic reaction. Less frequently, hypotension and angioedema may also occur. Symptoms may be treated or prevented with antihistamines, including diphenhydramine, and are less likely to occur with slow infusion.

Therapeutic drug monitoring

Vancomycin activity is considered to be time-dependent – that is, antimicrobial activity depends on the duration that the drug level exceeds the minimum inhibitory concentration (MIC) of the target organism. Thus, peak levels have not been shown to correlate with efficacy or toxicity – indeed concentration monitoring is unnecessary in most cases. Circumstances where therapeutic drug monitoring (TDM) is warranted include: patients receiving concomitant aminoglycoside therapy, patients with (potentially) altered pharmacokinetic parameters, patients on haemodialysis, during high dose or prolonged treatment, and patients with impaired renal function. In such cases, trough concentrations are measured.

The levels aimed for have changed over the years. Early authors suggested peak levels of 30 to 40 mg/L and trough levels of 5 to 10 mg/L, but current recommentations are that peak levels need not be measured and that for serious infections, trough levels of 15 to 20 mg/L should be aimed for.

Toxicity

Vancomycin has traditionally been considered a nephrotoxic and ototoxic drug, based on observations by early investigators of elevated serum levels in renally impaired patients who had experienced ototoxicity, and subsequently through case reports in the medical literature. However, as the use of vancomycin increased with the spread of MRSA beginning in the seventies, it was recognised that the previously reported rates of toxicity were not being observed. This was attributed to the removal of the impurities present in the earlier formulation of the drug, although those impurities were not specifically tested for toxicity.

Nephrotoxicity

Subsequent reviews of accumulated case reports of vancomycin-related nephrotoxicity found that many of the patients had also received other known nephrotoxins, particularly aminoglycosides. Most of the rest had other confounding factors, or insufficient data regarding the possibility of such, that prohibited the clear association of vancomycin with the observed renal dysfunction.

In 1994, Cantu and colleagues found that the use of vancomycin monotherapy was clearly documented in only three of 82 available cases in the literature. Prospective and retrospective studies attempting to evaluate the incidence of vancomycin-related nephrotoxicity have largely been methodologically flawed and have produced variable results. The most methodologically sound investigations indicate that the actual incidence of vancomycin-induced nephrotoxicity is around 5–7%. To put this into context, similar rates of renal dysfunction have been reported for cefamandole and benzylpenicillin, two reputedly non-nephrotoxic antibiotics.

Additionally, evidence to relate nephrotoxicity to vancomycin serum levels is inconsistent. Some studies have indicated an increased rate of nephrotoxicity when trough levels exceed 10 µg/mL, but others have not reproduced these results. Nephrotoxicity has also been observed with concentrations within the "therapeutic" range as well. Essentially, the reputation of vancomycin as a nephrotoxin is over-stated, and it has not been demonstrated that maintaining vancomycin serum levels within certain ranges will prevent its nephrotoxic effects, when they do occur.

Ototoxicity

Attempts to establish rates of vancomycin-induced ototoxicity are even more difficult due to the scarcity of quality evidence. The current consensus is that clearly related cases of vancomycin ototoxicity are rare. The association between vancomycin serum levels and ototoxicity is also uncertain. While cases of ototoxicity have been reported in patients whose vancomycin serum level exceeded 80 µg/mL, cases have been reported in patients with therapeutic levels as well. Thus, it also remains unproven that therapeutic drug monitoring of vancomycin for the purpose of maintaining "therapeutic" levels will prevent ototoxicity.

Interactions with other nephrotoxins

Another area of controversy and uncertainty concerns the question of whether, and if so, to what extent, vancomycin increases the toxicity of other nephrotoxins. Clinical studies have yielded variable results, but animal models indicate that there probably is some increased nephrotoxic effect when vancomycin is added to nephrotoxins such as aminoglycosides. However, a dose- or serum level-effect relationship has not been established.

Antibiotic resistance

Intrinsic resistance

There are a few gram-positive bacteria that are intrinsically resistant to vancomycin: these are Leuconostoc and Pediococcus species, but these organisms are rare causes of disease in humans. Most Lactobacillus species are also intrinsically resistant to vancomycin (the exception is the finding of a few strains (but not all) of L. acidophilus).

Most gram-negative bacteria are intrinsically resistant to vancomycin because their outer membrane is impermeable to large glycopeptide molecules (with the exception of some non-gonococcal Neisseria species).

Acquired resistance

Acquired microbial resistance to vancomycin is a growing problem, particularly within health care facilities such as hospitals. With vancomycin being the last-line antibiotic for serious Gram-positive infections there is the growing prospect that resistance will result in a return to the days when fatal bacterial infections were common. Vancomycin-resistant enterococcus (VRE) emerged in 1987. Vancomycin resistance emerged in more common pathogenic organisms during the 1990s and 2000s, including vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), and vancomycin-resistant Clostridium difficile. There is some suspicion that agricultural use of avoparcin, another similar glycopeptide antibiotic, has contributed to the emergence of vancomycin-resistant organisms.

One mechanism of resistance to vancomycin appears to be alteration to the terminal amino acid residues of the NAM/NAG-peptide subunits, normally D-alanyl-D-alanine, which vancomycin binds to. Variations such as D-alanyl-D-lactate and D-alanyl-D-serine result in only a 4-point hydrogen bonding interaction being possible between vancomycin and the peptide. This loss of just one point of interaction results in a 1000-fold decrease in affinity.

In Enterococci this modification appears to be due to the expression of an enzyme which alters the terminal residue. Three main resistance variants have been characterised to date among resistant Enterococcus faecium and E. faecalis populations.

VanA - resistance to vancomycin and teicoplanin, inducible on exposure to these agents
VanB - lower level resistance, inducible by vancomycin but strains may remain susceptible to teicoplanin
VanC - least clinically important, resistance only to vancomycin, constitutive resistance

The development and use of novel antibiotics such as linezolid and daptomycin is expected to delay, but not halt, the emergence of bacteria resistant to all available antibiotics.

See also

Drug resistance
Antibiotic resistance
Methicillin-resistant Staphylococcus aureus
Vancomycin-resistant Staphylococcus aureus
Vancomycin-resistant enterococcus

Trade names

Trade names and prices of vancomycin

Name Information Price* Quantity
       
Vancocin 125mg 20 capsules (vancomycin) $170 20 capsules
Vancocin 250mg 20 capsules (vancomycin) $333 20 capsules
Generic Vancomycin 250mg 28 capsule $316 28 capsule
Generic Vancomycin Injection (1 x 10ml) 500mg 1 vials Vancomycin (Vancomycin Hydrochloride) $49 1 vials
Generic Vancomycin Injection (1 x 20ml) 1g 1 vials Vancomycin (Vancomycin Hydrochloride) $64 1 vials

*) Prices related to some of online drugstores. There are only approximate prices. For some of drugs is needed a prescription.

Tags

Keywords related to vancomycin

niaspan cetrotide alglucerase viroptic benidipine cinchophen minocycline indalpine lortab diflorasone chemet nantradol lupron cold capsule v parsidol amitril barnidipine enocitabine dyazide ezetimibe simvastatin rapacuronium bromide dtpa dipyridamole erythromycin acistrate nuprin adrenalone chlorcyclizine acihexal invirase robaxisal ismo azopt interferon beta fluvastatin benoxaprofen chlorphenesin dalmane advicor pentasa cilastatin amfonelic acid bravelle acetorphine amitriptyline sarafloxacin teriparatide alrex biciromab asmalix rolziracetam iquix triclofos metitepine regonol


  • Related news


    Akorn, Inc. Launches Acular And Hydralazine Hydrochloride
    Akorn, Inc. announced that it has provided the following response regarding FDA's draft guidance on vancomycin hydrochloride (HCl) capsules. ...
    Read full article

    Federal Register 2008 - 73 FR 76362 Draft Guidance for Industry on
    There are no approved ANDAs for vancomycin HCl capsules. Vancomycin acts locally in the lower gastrointestinal (GI) tract. After oral administration ...
    Read full article

    Vancomycin-Resistant Enterococci (VRE)
    Vancomycin-resistant enterococci (VRE) are a type of bacteria called enterococci that have developed resistance to many antibiotics, especially vancomycin. ...
    Read full article

    of topical fixed-combination fortified vancomycinamikacin (VA
    In an in vitrostudy, fixed-combination fortified vancomycin and amikacin ophthalmic solutions (VA solution) had the same potency and stable physical ...
    Read full article

    Ceftaroline Noninferior to Vancomycin Plus Aztreonam for Complicated
    By Chris Berrie. HELSINKI, Finland -- May 22, 2009 -- As a monotherapy, ceftaroline (CFT) is well tolerated and provides high clinical cure and ...
    Read full article

    Article: Ceftobiprole rivals vancomycin-based combination for skin
    Ceftobiprole rivals vancomycin-based combination for skin infections.(Skin Disorders) find Family Practice News articles. Monotherapy with ceftobiprole ...
    Read full article

    Vancomycin for pneumonia
    Vancomycin kills bacteria by preventing them from reproducing. It is given through a vein (intravenously, or IV). Doctors use vancomycin to treat people who ...
    Read full article

    Increase of VRE at Sligo hospital
    In a statement the hospital said that the increase of Vancomycin Resistant Enterococci at the intensive care unit was identified as a result of on-going ...
    Read full article

    Teicoplanin Safe, as Effective as Vancomycin for Treating Patients
    By Chris Berrie. HELSINKI, Finland -- May 21, 2009 -- The glycopeptide antibiotic teicoplanin has an acceptable safety profile and is as effective as ...
    Read full article

    SMFM: High Rate of Inappropriate Vancomycin Prophylaxis in Labor and
    By Charles Bankhead, Staff Writer, MedPage Today. DALLAS, Feb. 4 -- Women given prophylactic vancomycin for perinatal group B streptococcal disease may lack ...
    Read full article

    Vancomycin (Intravenous Route, Injection Route)
    Housecall, our weekly general-interest e-newsletter, keeps you up to date on a wide variety of health topics with timely, reliable, practical information, ...
    Read full article

    Optimer Announces Presentation of Additional Data From Fidaxomicin
    However, the recurrence rate difference between fidaxomicin and vancomycin was even greater, 10.9% versus 24.3%, respectively, in patients who did not ...
    Read full article

    'Nanotech search' for antibiotics
    Antibiotics such as vancomycin bind to the bacterial cell wall, disrupting it and causing the bacteria to break down. When bacteria become resistant, ...
    Read full article

    Oral Linezolid as Effective as Intravenous Vancomycin in Treating
    By Chris Berrie. HELSINKI, Finland -- May 26, 2009 -- Oral linezolid (PO-LIN) shows similar overall adverse events (AEs) and comparable clinical cure rates ...
    Read full article

    Superbug shuts down elective surgery at Coffs
    VRE is resistant to the strong antibiotic Vancomycin so it limits treatment for seriously ill patients with major infections. ...
    Read full article

    Doctor's antibiotics led to man's paralysis: court
    The bacteria are also only partially controllable by vancomycin. Thus, due to the resistance, doctors could not use vancomycin and were unable to treat ...
    Read full article

    Superbug at hospital worse than golden staph
    The superbug, vancomycin-resistant enterococcus (VRE), is resistant to multiple types of antibiotics including vancomycin, commonly known as "the antibiotic ...
    Read full article

    Resistant bacteria 'probed'
    The system was able to detect that it is 1000 times harder for vancomycin to attach to resistant bacteria than to non-resistant bacteria. ...
    Read full article

    Microbe of the Month: Vancomycin-Resistant Enterococci (VRE)
    Enterococci bacteria grabbed the attention of public health officials in the 1980s because of its ability to survive in humans, as well as for its ...
    Read full article

    , LLC Announces FDA Approvals for Sterile Vancomycin HCl USP, 500
    Sterile Vancomycin HCl is an antibiotic indicated for the treatment of Recent IMS data estimates an annual market size for Sterile Vancomycin HCl of ...
    Read full article

    Successful control of vancomycin-resistant Enterococcus faecium
    KY Yuen, Carol Yu Centre for Infection, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong Special Administrative Region, China. Vancomycin-resistant ...
    Read full article

    Hospira Receives FDA Approval for 10 Gram Vial of Sterile Vancomycin
    "Approval of Hospira's 10 gram vial of vancomycin closely follows the FDA's recent Hospira now offers vancomycin in 500 milligram, 750 milligram, ...
    Read full article

    US panel backs plan for ViroPharma drug copies
    Many of the outside experts said there was a public health need for cheaper versions of oral vancomycin to fight a growing number of intestinal infections ...
    Read full article

    Targanta Presents Preclinical In Vivo Data Demonstrating Activity Of
    Oritavancin at 100 mg/kg exhibited superior efficacy to vancomycin at day 12: 100% survival was observed for animals treated with oritavancin compared to 0% ...
    Read full article

    Nanotechnology could be the next hope against superbug infections
    They found that compared to other common antibiotics, Vancomycin gives much An examination of the reaction of Vancomycin on the bacterial cells showed ...
    Read full article

    MRSA strain linked to high mortality rates
    MRSA strains can be resistant to many drugs, though they are typically susceptible to the antibiotic vancomycin. MRSA nfections are often treated with ...
    Read full article

    With AuricX Pharmaceuticals on Oral Formulations of Vancomycin
    Once considered the "drug of last resort," vancomycin is now commonly used in Vancomycin sales were more than $380 million and accounted for 85 percent ...
    Read full article

    Vancomycin's Benefits in C. difficile Declining
    Researchers found that vancomycin is no longer superior to metronidazole; Metronidazole and vancomycin have been the mainstays of therapy for ...
    Read full article

    Going Long on Two New Names
    Two antibiotics used to treat C. diff -- vancomycin and metronidazole -- do Both studies pit OPT-80 head-to-head against vancomycin, which is sold under ...
    Read full article

    Targanta drug appears similar to rival-US FDA staff
    Vancomycin is sold in a variety of formulations, including as a pill called Vancocin by ViroPharma Inc (VPHM.O) under license from Eli Lilly and Co (LLY.N). ...
    Read full article

    Monitoring vancomycin.(THE EFFECTIVE PHYSICIAN) Article from
    Monitoring vancomycin.(THE EFFECTIVE PHYSICIAN) find Internal Medicine News articles. Background Vancomycin has a reputation for potential nephro- and ...
    Read full article

    The Treatment of Community-Acquired MRSA Infections
    Recently the issue of vancomycin obsolescence was debated in the literature. For example, vancomycin concentration in lung epithelial lining fluid in ...
    Read full article

    Therapeutic monitoring of vancomycin.(CLINICAL GUIDELINES FOR
    Therapeutic monitoring of vancomycin.(CLINICAL GUIDELINES FOR FAMILY PHYSICIANS) find Family Practice News articles. Vancomycin is an antibiotic that is ...
    Read full article

    Ceftaroline noninferior to vancomycin/aztreonam.(INFECTIOUS DISEASE
    Ceftaroline noninferior to vancomycin/aztreonam.(INFECTIOUS DISEASE)(Report) find Internal Medicine News articles. WASHINGTON--The investigational ...
    Read full article

    Linezolid, Vancomycin Effective Against Skin Complication in Community
    By Ed Susman. SAN FRANCISCO -- September 17, 2009 -- Linezolid and vancomycin are clinically effective in the treatment of complicated skin and soft-tissue ...
    Read full article

    Persistent vancomycin and high-level gentamicin-resistant Enterococcus
    Correspondence: Dr N Hapnes, Apt 12 Temple Place, Grenville Street, Dublin 1, Ireland. E-mail: ninahapnes@hotmail.com. Vancomycin-resistant Enterococcus ...
    Read full article

    Arpida gets go-ahead for oral Iclaprim switch trial
    formulation of iclaprim as step-down therapy in comparison with intravenous (IV) vancomycin in the treatment of complicated skin diseases, Arpida said. ...
    Read full article

    Antibiotic use increases at academic medical centers
    "The other change contributing to the increase in total use was the marked increase in the use of vancomycin," the authors write. ...
    Read full article

    Charlottetown hospital reports more superbug cases
    The Queen Elizabeth Hospital has reported a total of eight cases of vancomycin resistant enterococci, or VRE, since May. One patient with VRE remains in ...
    Read full article

    approves test for a gene linked to resistance to the antibiotic
    The vanA gene is the gene most commonly associated with vancomycin resistance. The test runs on Cepheid's GeneXpert System and can detect the vanA gene in ...
    Read full article

    Vancomycin HCl USP, 500 Mg/Vial; 1 G/Vial And Sterile Vancomycin
    Akorn-Strides, LLC announced that the US Food and Drug Administration has granted approvals for two Abbreviated New Drug Applications (ANDAs) for Sterile ...
    Read full article

    Structure of Antibiotic Ramoplanin Shows Promising Mechanism
    With the "last resort" antibiotic Vancomycin now plagued by the first signs It arrives at a time when Vancomycin, the antibiotic physicians rely on when ...
    Read full article

    Forest anti-infective hits main goal in studies
    "Ceftaroline-treated patients had a clinical cure rate of 91.6 percent compared to a vancomycin plus aztreonam clinical cure rate of 92.7 percent," Forest ...
    Read full article

    Using Linezolid Instead of Vancomycin to Treat Serious Infections
    By Ed Susman. PHILADELPHIA -- November 1, 2009 -- Treatment with the antibiotic linezolid appears to prevent fewer rehospitalisations than does vancomycin ...
    Read full article

    Metronidazole as Effective as Vancomycin for Clostridium Difficile
    By Chris Berrie. BARCELONA, Spain -- April 24, 2008 -- Metronidazole is noninferior to vancomycin for patients with Clostridium difficile-associated ...
    Read full article

    Reduction in vancomycin susceptibility may occur in MSSA
    Reduced vancomycin susceptibility can occur in Staphylococcus aureus regardless of background methicillin susceptibility, according to findings published ...
    Read full article

    Ceftaroline Demonstrates Efficacy Against Complicated Skin Infections
    Ceftaroline, a broad-spectrum cephalosporin being developed by Forest Laboratories, Inc., demonstrated comparable efficacy to vancomycin/ aztreonam ...
    Read full article

    Hospitals use more antibiotics despite concerns
    is rising despite concerns about fueling bacterial resistance, with Wyeth's Zosyn and the older drug vancomycin driving the trend, researchers said. ...
    Read full article

    Return of the bug busters: the fight against 'Superbugs' is now
    Currently, MRSA is treated with vancomycin, a glycopeptide that inhibits peptidoglycan synthesis. However, telavancin, also a glycopeptide, disrupts the ...
    Read full article

    Targanta Therapeutics presents preclinical data on Oritavancin
    has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster ...
    Read full article